Business
Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development,
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":"BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that 12-month data from the U.S.-based Phase 1 trial evaluating OTX-TKI for the treatment of wet AMD will be presented at the 2023 Clinical Trials at the Summit Annual Meeting being held on June 10th in Park City, Utah. The Company will also participate in a panel discussing the challenges of bringing novel treatments to the market. Ocular Therapeutix is also sponsoring a presentation discussing the Company's proprietary bioresorbable hydrogel-based formulation technology and retina focused clinical programs. A conference call discussing the 12-month data from the U.S.-based Phase 1 clinical trial of OTX-TKI presented at the Clinical Trials at the Summit will be hosted by the Ocular Therapeutix management team on Monday, June 12th at 8:30 AM ET. “We look forward to presenting the 12-month data update from our U.S.-based trial evaluating OTX-TKI for the treatment of wet AMD,” stated Rabia Gurses Ozden, MD, Chief Medical Officer of Ocular Therapeutix. “Our most recent update at 10-months observed that CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects with a 92% reduction in treatment burden in the OTX-TKI arm. This new data will include additional information regarding the pharmacodynamics of OTX-TKI at month 12.” Presentations at Clinical Trials at the Summit: 12-Month Update on Randomized, Controlled, Trial of OTX-TKI (Axitinib Intravitreal Implant) for the Treatment of Wet AMDDate / Time: Saturday, June 10th at 4:29 PM MDTPresenter: Arshad M. Khanani, MD, Director of Clinical Research at Sierra Eye AssociatesThe presentation will be posted on the Company’s website at approximately 4:30 PM MDT the same day under the Investors tab, Events and Presentations/Scientific and Medical Presentations. Challenges of Bringing Novel Treatment Options to the MarketPanel Date/Times: Saturday, June 10th at 10:44 AM MDTPanelists: Mohamed Genead, Alexander Hardy, Antony Mattessich, Reenie McCarthy, Joel Naor, Victor PerlrothModerator: Jeffrey Heier, MD, Director of the Vitreoretinal Service and Retina Research at Ophthalmic ...